China Goserelin Market Report 2021: A Synthetic Analogue of a Naturally Occurring Gonadotropin-Releasing Hormone – Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Goserelin Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and prostate cancer. In 1996, 3.6 mg of Goserelin was approved to enter the Chinese market, and in 2012, 10.8 mg of Goserelin was approved to enter the Chinese market and has been included in China’s Class B medical insurance catalog. By the end of 2020, the only manufacturer in China is AstraZeneca UK Ltd.

According to the market research, the sales value of Goserelin in the Chinese market has increased year by year since 2016-2020, with the CAGR from 2016 to 2019 is around 18%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the annual growth rate of Goserelin’s sales value dropped to 8.76% in 2020.

However, the sales value of Goserelin in the Chinese market reached CNY990 million in 2020 and the CAGR of the sales value of Goserelin in the Chinese market is 15.94% from 2016 to 2020.

The analyst predicts that with the increase in the number of patients with indications, the sales volume of Goserelin will steadily increase from 2021 to 2025.

In 2020, the number of new breast cancers worldwide reached 2.26 million, and the number of prostate cancers was 1.41 million, both of which were on the rise. Therefore, the sales volume of Goserelin for the treatment of breast cancer and prostate cancer increased with the increase in the number of patients diagnosed with breast cancer and prostate cancer, and its sales also increased.

China has approved Luye Pharmaceuticals to conduct generic drug clinical trials and has successfully conducted Phase III clinical trials at the end of 2020. It is expected that the generic drug will be launched in the next five years. As a result, the price of Goserelin will continue to fall, sales and sales volume will also have certain upside potential. In addition, the effective alleviation of COVID-19 will also cause a recovery growth in the sales of Goserelin.

Topics Covered:

• The impact of COVID-19 on China’s Goserelin market
• Sales value of China’s Goserelin 2016-2020
• Competitive landscape of China’s Goserelin market
• Prices of Goserelin in China
• Prices of Goserelin in China by regions and manufacturers
• Analysis of factors affecting the development of China’s Goserelin market
• Prospect of China’s Goserelin market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Goserelin

1.1 Indications for Goserelin

1.2 Development of Goserelin in China

1.3 Governmental Approval of Goserelin in China

1.4 The Impact of COVID-19 on Goserelin sales in China

2 Sales of Goserelin in China, 2016-2020

2.1 Sales Value of Goserelin

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Goserelin

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Goserelin by Dosage Form in China, 2016-2020

2.3.1 Sustained-release Implant Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Goserelin Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Goserelin Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales Volume

3.2 AstraZeneca UK Ltd

3.2.1 Enterprise Profile

3.2.2 Sales of ZOLADEX (AstraZeneca UK Ltd’s Goserelin) in China

4 Prices of Goserelin for Different Manufacturers in China, 2020-2021

4.1 AstraZeneca UK Ltd (ZOLADEX)

4.2 Analysis of Other Manufacturers

5 Prospect of Chinese Goserelin Market, 2021-2025

5.1 Influential Factors of Chinese Goserelin Market Development

5.1.1 The Impact of COVID-19 on Chinese Goserelin Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/usghb8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900